Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789576 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
A Phase 4 study of Psoriasis, sponsored by Organon and.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 10
- Study locations
NCT05789576: Completed Phase 4 study of Psoriasis, sponsored by Organon and.
NCT05789576 is a Phase 4 study of Psoriasis that has completed, run by Organon and. The registered enrollment target is 31 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05789576, a Phase 4 study of Psoriasis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region
Primary Outcome
Physician Global Assessment (PGA) is a clinical tool for assessing the current state/severity of a participant's psoriasis in a target lesion of the head and neck region at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the head and neck region. The PGA ranges from 0 to 4, and is assessed as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores re
Conditions Studied
Interventions
- DRUG VTAMA (tapinarof) cream, 1%
Study Locations (10)
Michigan
- Dermavant Investigative Site - Auburn Hills
- Dermavant Investigative Site - Detroit
Georgia
- Dermavant Investigative Site - Macon
Illinois
- Dermavant Investigative Site - Chicago
Maryland
- Dermavant Investigative Sites - Rockville
Nevada
- Dermavant Investigative Site - Las Vegas
New Hampshire
- Dermavant Investigative Site - Portsmouth
New York
- Dermavant Investigative Site - Kew Gardens
Ohio
- Dermavant Investigative Site - Marion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 4 |
What the finished NCT05789576 record still lists
NCT05789576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which VTAMA (tapinarof) cream, 1% is the first listed.
NCT05789576 lists 10 locations in 9 states (Michigan, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT05789576 about?
NCT05789576 is a clinical study titled "A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region". This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region
What is the current status of trial NCT05789576?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2023-03-13. Estimated completion is 2023-07-19.
What conditions does trial NCT05789576 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05789576?
The interventions under investigation include: VTAMA (tapinarof) cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05789576?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789576 being conducted?
This trial has 10 study locations across Georgia, Illinois, Maryland, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05789576's enrollment target sits among peer trials
31 92nd of 125 higher than 32 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI